Artículo

Safety and immunogenicity of a SARS-CoV-2 Gamma variant RBD-based protein adjuvanted vaccine used as booster in healthy adults

Pasquevich, Karina Alejandra Icon; Coria, Mirta Lorena Icon; Ceballos, Ana Icon; Mazzitelli, Bianca ; Rodriguez, Juan Manuel ; Demaría, María Agostina Icon; Pueblas Castro, Celeste Victoria Icon; Bruno, Laura ; Saposnik, Lucas Martín Icon; Salvatori, Melina Icon; Varese, Augusto Icon; González, Soledad ; González Martínez, Verónica V. Icon; Geffner, Jorge Raúl Icon; Álvarez, Diego ; del Priore, Sabrina Alejandra ; Hernando Insua, Andrés C. ; Kaufmann, Ingrid G. ; Di María, Adrián ; Góngora, Adrián ; Sasso, Guillermina ; Stamer, Sebastián ; Cardoso, Regina ; Chajet, Alejandro ; de Oca, Federico Montes ; Vega, Julio ; Lombardo, Daniela Mónica ; Yerino, Gustavo A. ; Fló, Juan ; Cassataro, Juliana Icon

Otros responsables

Fecha

12/2023

Editorial

Nature Research

Revista

Nature Communications

Título del libro

Nombre del evento

Fecha del evento

Institución organizadora

ISSN

2041-1723

eISSN

ISBN

Idioma

Inglés

Tipo del evento

Clasificación temática

Resumen

A Gamma Variant RBD-based aluminum hydroxide adjuvanted vaccine called ARVAC CG was selected for a first in human clinical trial. Healthy male and female participants (18-55 years old) with a complete COVID-19-primary vaccine scheme were assigned to receive two intramuscular doses of either a low-dose or a high-dose of ARVAC CG. The primary endpoint was safety. The secondary objective was humoral immunogenicity. Cellular immune responses were studied as an exploratory objective. The trial was prospectively registered in PRIISA.BA (Registration Code 6564) and ANMAT and retrospectively registered in ClinicalTrials.gov (NCT05656508). Samples from participants of a surveillance strategy implemented by the Ministry of Health of the Province of Buenos Aires that were boosted with BNT162b2 were also analyzed to compare with the booster effect of ARVAC CG. ARVAC CG exhibits a satisfactory safety profile, a robust and broad booster response of neutralizing antibodies against the Ancestral strain of SARS-CoV-2 and the Gamma, Delta, Omicron BA.1 and Omicron BA.5 variants of concern and a booster effect on T cell immunity in individuals previously immunized with different COVID-19 vaccine platforms.

Aprobación

Revisión

Complementado por

Referenciado por

Licencia Creative Commons

Excepto donde se indique lo contrario, la licencia de este ítem se describe como by-nc-sa